

General information about company		
Scrip code	506820	
NSE Symbol	ASTRAZEN	
MSEI Symbol	NOTLISTED	
ISIN	INE203A01020	
Name of the entity	ASTRAZENECA PHARMA INDIA LIMITED	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Reporting Quarter Type	Yearly	
Date of Quarter Ending	31-03-2025	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	Disclosure related to acquisition of shares or voting rights in unlisted companies is not applicable to the Company.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	Disclosure related to imposition of fine or penalty is not applicable to the Company.
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes	
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	The Company has not provided loans, granted guarantees, comfort letters, securities.
Risk management committee	Applicable	
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities	
Is SCORE ID Available ?	Yes	
SCORE Registration ID	A00366	
Reason For No SCORE ID		
Type of Submission	Original	
Remarks (website dissemination)		
Remarks for Exchange (not for Website Dissemination)		

Annexure I								
Annexure I to be submitted by listed entity on quarterly basis								
I. Composition of Board of Directors								
Disclosure of notes on composition of board of directors explanatory								
Whether the listed entity has a Regular Chairperson							Yes	
Whether Chairperson is related to MD or CEO							No	
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Ms	SHILPA DIVEKAR NIRULA	AAHPD1574B	06619353	Non-Executive - Independent Director	Chairperson		30-11-1973
2	Ms	REVATHY ASHOK	ACLPR3951Q	00057539	Non-Executive - Independent Director	Not Applicable		16-01-1959
3	Ms	MONICA WIDHANI	AASPW5303N	07674403	Non-Executive - Independent Director	Not Applicable		18-01-1959
4	Mr	SANJEEV KUMAR PANCHAL	AHUPP0659F	09823879	Executive Director	Not Applicable		11-08-1977
5	Mr	JESUS JAVIER DIAZ-ROPERO ESTESO	ZZZZZ9999Z	10835384	Non-Executive - Non Independent Director	Not Applicable		05-02-1972
6	Ms	SYLVIA LORENA VARELA RAMON	ZZZZZ9999Z	10410837	Non-Executive - Non Independent Director	Not Applicable		20-03-1966
7	Ms	HOOI BIEN CHUAH	ZZZZZ9999Z	10381891	Non-Executive - Non Independent Director	Not Applicable		17-01-1975
8	Ms	BHAVANA AGRAWAL	AFMPA5396L	10485441	Executive Director	Not Applicable		04-11-1978

I. Composition of Board of Directors													
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		29-12-2021	29-12-2021		39.03	2	2	2	0			
2	NA		02-12-2016	02-12-2021		99.29	5	5	10	3			
3	NA		25-09-2024	25-09-2024		6.05	5	5	8	3			
4	NA		01-01-2023				1	0	1	0			
5	NA		13-11-2024				1	0	0	0		Textual Information(1)	
6	NA		21-12-2023				1	0	1	1		Textual Information(2)	
7	NA		09-11-2023				1	0	1	0		Textual Information(3)	
8	NA		08-02-2024				1	0	1	0			

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	07674403	MONICA WIDHANI	Non-Executive - Independent Director	Chairperson	25-09-2024		
2	06619353	SHILPA DIVEKAR NIRULA	Non-Executive - Independent Director	Member	08-02-2022		
3	10381891	HOOI BIEN CHUAH	Non-Executive - Non Independent Director	Member	08-02-2024		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Chairperson	08-02-2022		
2	06619353	SHILPA DIVEKAR NIRULA	Non-Executive - Independent Director	Member	25-09-2024		
3	10410837	SYLVIA LORENA VARELA RAMON	Non-Executive - Non Independent Director	Member	28-05-2024		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	10410837	SYLVIA LORENA VARELA RAMON	Non-Executive - Non Independent Director	Chairperson	08-02-2024		
2	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Member	02-02-2017		
3	09823879	SANJEEV KUMAR PANCHAL	Executive Director	Member	01-01-2023		
4	10485441	BHAVANA AGRAWAL	Executive Director	Member	08-02-2024		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	07674403	MONICA WIDHANI	Non-Executive - Independent Director	Chairperson	25-09-2024		
2	09823879	SANJEEV KUMAR PANCHAL	Executive Director	Member	01-01-2023		
3	10485441	BHAVANA AGRAWAL	Executive Director	Member	08-02-2024		
4	99999999	SRIKANTH B S	Site Lead - India Operations	Member	08-08-2024		Textual Information(1)
5	99999999	AMARPREET KAUR AHUJA	Country HR Director	Member	03-08-2020		Textual Information(2)

Sr Text Block	
Textual Information(1)	Mr. Srikanth B.S. is not a Director, hence DIN is not available.
Textual Information(2)	Ms. Amarpreet Kaur Ahuja is not a Director, hence DIN is not available.

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	10381891	HOOI BIEN CHUAH	Non-Executive - Non Independent Director	Chairperson	08-02-2024		
2	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Member	02-02-2017		
3	09823879	SANJEEV KUMAR PANCHAL	Executive Director	Member	01-01-2023		

Annexure 1								
Annexure 1								
III. Meeting of Board of Directors								
Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	13-11-2024				Yes	8	7	2
2	18-12-2024		34		Yes	8	5	2
3		11-02-2025	54		Yes	8	7	3
4		04-03-2025	20		Yes	8	7	3
5		04-03-2025			Yes	8	5	2
6		26-03-2025	21		Yes	8	7	3

Annexure 1

IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	13-11-2024				Yes	4	3	2	0
2	Audit Committee	11-02-2025	89			Yes	3	2	2	0
3	Nomination and remuneration committee	13-11-2024				Yes	3	3	2	0
4	Nomination and remuneration committee	04-03-2025	110			Yes	3	2	2	0
5	Nomination and remuneration committee	04-03-2025				Yes	3	2	2	0
6	Stakeholders Relationship Committee	13-11-2024				Yes	4	4	1	0

Annexure 1										
IV. Meeting of Committees										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Risk Management Committee	11-02-2025				Yes	5	3	1	2

Annexure 1**V. Affirmations**

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	Manasa. R
2	Designation	Company Secretary and Compliance Officer

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**I. Disclosure on website in terms of LODR Regulation**

Sr				
Sr	Item	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.	Web address
	As per regulation 46(2) of the LODR:			
1.1	Details of business	Yes		www.astrazeneca.com/india
1.2	Memorandum of Association and Articles of Association	Yes		www.astrazeneca.com/india
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		www.astrazeneca.com/india
2	Terms and conditions of appointment of independent directors	Yes		www.astrazeneca.com/india
3	Composition of various committees of board of directors	Yes		www.astrazeneca.com/india
4	Code of conduct of board of directors and senior management personnel	Yes		www.astrazeneca.com/india
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		www.astrazeneca.com/india
6	Criteria of making payments to non-executive directors	NA		
7	Policy on dealing with related party transactions	Yes		www.astrazeneca.com/india
8	Policy for determining ‘material’ subsidiaries	NA		
9	Details of familiarization programmes imparted to independent directors	Yes		www.astrazeneca.com/india
10	Email address for grievance redressal and other relevant details	Yes		www.astrazeneca.com/india
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		www.astrazeneca.com/india
12	Financial results	Yes		www.astrazeneca.com/india
13	Shareholding pattern	Yes		www.astrazeneca.com/india
14	Details of agreements entered into with the media companies and/or their associates	NA		

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)			
I. Disclosure on website in terms of LODR Regulation			
Sr			
	As per regulation 46(2) of the LODR:		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes	www.astrazeneca.com/india
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	NA	
16	New name and the old name of the listed entity	NA	
17	Advertisements as per regulation 47 (1)	Yes	www.astrazeneca.com/india
18	Credit rating or revision in credit rating obtained	NA	
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	NA	
20	Secretarial Compliance Report	Yes	www.astrazeneca.com/india
21	Materiality Policy as per Regulation 30 (4)	Yes	www.astrazeneca.com/india
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes	www.astrazeneca.com/india
23	Disclosures under regulation 30(8)	Yes	www.astrazeneca.com/india
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA	
25	Dividend Distribution policy as per Regulation 43A(1)	Yes	www.astrazeneca.com/india
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	www.astrazeneca.com/india
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA	
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes	www.astrazeneca.com/india
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	www.astrazeneca.com/india

Annexure II**II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of ‘independence’ and/or ‘eligibility’	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	NA	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

Annexure II**II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

Annexure II**II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	NA	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	NA	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	NA	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	NA	
	Any other information to be provided - Add Notes			

Annexure II		
1	Name of signatory	Manasa. R
2	Designation	Company Secretary and Compliance Officer

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	NA
	Any other information to be provided	

Annexure II		
1	Name of signatory	Manasa. R
2	Designation	Company Secretary and Compliance Officer

Details of Cyber security incidence		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		Yes
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		1
Sr.	Date of the event	Brief details of the event
1	22-12-2024	1. The Company's Twitter account was unexpectedly locked or hacked, and are unable to retrieve it. The Company have informed the AstraZeneca Global Cyber Security team and have contacted Twitter Support requesting for the account to be unlocked/ recovered. 2. An FIR has also been filed with the Cyber Crime Unit, Bangalore. 3. Currently no malicious content have been posted from our Twitter handle.

Signatory Details	
Name of signatory	Manasa. R
Designation of person	Company Secretary and Compliance Officer
Place	Bangalore
Date	29-04-2025

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
1	The office of Deputy Commissioner of Income Tax, TP 1(1) (1), Bangalore	15-04-2025	Company has received an order from the Transfer Pricing Officer being issued under section 92 CA (3) of the Income Tax Act, 1961 for assessment year 2022-23, wherein adjustment on the legacy issues has been proposed.	The matter will be challenged before appropriate appellate forum, once the draft order is received. The expected overall financial implication cannot be determined at this stage. It will be determined only upon passing of the final assessment order for the assessment year 2022-23. However, quantum of claim as per the captioned order is Rs. 11.96 crores (approx.) excluding interest and penalty.
2	Assessment Unit, Income Tax Department	15-04-2025	Company has received a draft order from the Assessment Unit being passed under section 144C(1) read with section 143(3) of the Income Tax Act, 1961 for assessment year 2022-23, wherein adjustment on the legacy transfer pricing issues have been proposed.	The matter will be challenged before the Dispute Resolution Panel by filing an appeal. The expected overall financial implication cannot be determined at this stage. It will be determined only upon passing of the final assessment order for the assessment year 2022- 23. However, quantum of claim as per the captioned order is Rs. 11.96 crores (approx.) excluding interest and penalty.
3	Assistant Commissioner of Income tax	28-11-2018	Company has received a draft Order Giving Effect to the order of Hon'ble Income-tax Appellate Tribunal, being passed under section 144C(1) read with section 143(3) of the Income Tax Act, 1961 for assessment year 2014-15, wherein major adjustments done on the transfer pricing as well as corporate tax issues have been deleted.	The present order is a draft Order Giving Effect to the order of Hon'ble Income-tax Appellate Tribunal. The quantum of tax relief as per the captioned order is Rs. 35.22 crores (approx.) excluding interest.